Induction and tolerization of anti-male CD8(+) cytotoxic T lymphocytes by in vivo immunization with an H-Y-derived peptide

Citation
G. Sireci et al., Induction and tolerization of anti-male CD8(+) cytotoxic T lymphocytes by in vivo immunization with an H-Y-derived peptide, HUMAN IMMUN, 60(9), 1999, pp. 764-773
Citations number
35
Categorie Soggetti
Immunology
Journal title
HUMAN IMMUNOLOGY
ISSN journal
01988859 → ACNP
Volume
60
Issue
9
Year of publication
1999
Pages
764 - 773
Database
ISI
SICI code
0198-8859(199909)60:9<764:IATOAC>2.0.ZU;2-1
Abstract
We have analyzed the immune response induced by a 9mer synthetic peptide de rived from the male histocompatibility antigen H-Y and containing D-b-bindi ng motifs in C57BL/6 mice. In this study we report that a single, subcutaneous injection of the peptid e emulsified in IFA Save rise to the development of male-specific CD8(+) T cells which displayed H-Y-specific proliferative response in vitro and show ed a Tcl-type pattern of cytokine production (i.e. they secreted IFN-gamma and IL-2, but not. IL-4 and IL-10). Development of a strong cytotoxic activ ity required in vitro stimulation with specific peptide and IL-2: under the se culture conditions, we were able to generate potent CD8(+) CTLs that lys ed both male cells and peptide-pulsed female cells. Continuous administration of soluble peptide, delivered over a 7-day period by a mini-osmotic pump implanted subcutaneously, inhibited proliferative a nd cytotoxic responses and IFN-gamma production in lymph node cells from C5 7BL/6 mice subsequently primed with peptide in adjuvant. This decreased res ponses were associated with a strong increase in the secretion of IL-4 by a ntigen-specific CD8(+) T lymphocytes, Subcutaneous administration of the H-Y-peptide in adjuvant significantly ac celerates rejection of male skin graft, while continuous administration of peptide in soluble form did not modify the time course of rejection. (C) Am erican Society for Histocompatibility and Immunogenetics, 1999. Published b y Elsevier Science Inc.